Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Julia Piasecki | Researchclopedia

Back to researchers

Julia Piasecki

Bristol-Myers Squibb (United States)

69

Works

1,240

Citations

9

h-index

9

i10-index

Research Topics

Multiple Myeloma Research and Treatments CAR-T cell therapy research Protein Degradation and Inhibitors

Affiliations

Amgen (United States)2006–2017

Emory University2023–2023

Bristol-Myers Squibb (Germany)2025–2025

Université Paris Cité2023–2023

Centre Hospitalier Universitaire de Nantes2023–2023

Top Works

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

Paula Rodríguez‐Otero,Sikander Ailawadhi,et al.

2023650 citations

Monoclonal and Polyclonal Antibodies Research

Biosimilars and Bioanalytical Methods

Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor Activity

Jonathan D. Graves,Jennifer J. Kordich,et al.

2014154 citations

JCARH125, Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1/2 Multicenter Study (EVOLVE)

Sham Mailankody,Myo Htut,et al.

2018124 citations

Local Delivery of OncoVEXmGM-CSF Generates Systemic Antitumor Immune Responses Enhanced by Cytotoxic T-Lymphocyte–Associated Protein Blockade

Achim K. Moesta,Keegan S. Cooke,et al.

2017104 citations

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Sikander Ailawadhi,Bertrand Arnulf,et al.

202453 citations

Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis

Pamela M. Holland,Robert E. Miller,et al.

201039 citations

Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3

Paula Rodríguez‐Otero,Sikander Ailawadhi,et al.

202315 citations

Orvacabtagene Autoleucel (orva-cel; JCARH125): A Fully Human BCMA-Targeted Second-Generation CAR T Cell Product Characterized By a Predominant Central Memory Phenotype with High in Vitro and In Vivo Proliferative Potential and Sustained In Vivo Persistence

Lucrezia Colonna,Garnet Navarro,et al.

202015 citations

Anakinra (AKR) prophylaxis (ppx) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) receiving orvacabtagene autoleucel (orva-cel).

Luciano J. Costa,Sham Mailankody,et al.

202112 citations